Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer

MeSH terms

• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use
• Bone Neoplasms / drug therapy
• Bone Neoplasms / radiotherapy
• Bone Neoplasms / secondary
• Brachytherapy / adverse effects
• Clinical Decision-Making
• Docetaxel
• Humans
• Male
• Neoplasm Metastasis
• Prostatic Neoplasms, Castration-Resistant / drug therapy*
• Prostatic Neoplasms, Castration-Resistant / pathology
• Prostatic Neoplasms, Castration-Resistant / radiotherapy*
• Radium / adverse effects
• Radium / therapeutic use*
• Taxoids / adverse effects
• Taxoids / therapeutic use*
• Treatment Outcome